CN110511215B - Aryl piperazine/piperidine compound and application thereof - Google Patents
Aryl piperazine/piperidine compound and application thereof Download PDFInfo
- Publication number
- CN110511215B CN110511215B CN201810494866.0A CN201810494866A CN110511215B CN 110511215 B CN110511215 B CN 110511215B CN 201810494866 A CN201810494866 A CN 201810494866A CN 110511215 B CN110511215 B CN 110511215B
- Authority
- CN
- China
- Prior art keywords
- salt
- propyl
- fluoro
- compound
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Aryl piperazine Chemical compound 0.000 title claims abstract description 72
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 80
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 16
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 7
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 6
- 229960003638 dopamine Drugs 0.000 claims abstract description 6
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical class O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 2
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 claims description 2
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 229940071162 caseinate Drugs 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 150000001944 cysteine derivatives Chemical class 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical class C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- 239000001177 diphosphate Substances 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- 125000000741 isoleucyl group Chemical class [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 2
- 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000002823 nitrates Chemical class 0.000 claims description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 2
- 150000002994 phenylalanines Chemical class 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 150000003147 proline derivatives Chemical class 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000002987 valine group Chemical class [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000002333 glycines Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 34
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000009977 dual effect Effects 0.000 abstract description 5
- 239000002464 receptor antagonist Substances 0.000 abstract description 3
- 229940044551 receptor antagonist Drugs 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 129
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000002904 solvent Substances 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 238000009987 spinning Methods 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000005457 ice water Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000003042 antagnostic effect Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 4
- 108050004812 Dopamine receptor Proteins 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 3
- 208000027776 Extrapyramidal disease Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- PMLMARMRSAEQFX-UHFFFAOYSA-N N-[3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propyl]-N-propylbenzamide Chemical compound ClC1=C(C=CC=C1Cl)N1CCN(CC1)CCCN(C(C1=CC=CC=C1)=O)CCC PMLMARMRSAEQFX-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- NLSKESNFYRUZEB-UHFFFAOYSA-N 3-[1-(3-chloropropyl)piperidin-4-yl]-6-fluoro-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1C1CCN(CCCCl)CC1 NLSKESNFYRUZEB-UHFFFAOYSA-N 0.000 description 2
- MRMGJMGHPJZSAE-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1C1CCNCC1 MRMGJMGHPJZSAE-UHFFFAOYSA-N 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- AJZCTVAJRNIZDW-UHFFFAOYSA-N COC1=C(C=CC=C1)N1CCN(CC1)CCCN(C(C1=CC=CC=C1)=O)CCC Chemical compound COC1=C(C=CC=C1)N1CCN(CC1)CCCN(C(C1=CC=CC=C1)=O)CCC AJZCTVAJRNIZDW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000020358 Learning disease Diseases 0.000 description 2
- SMPWWFQZWFWYBE-UHFFFAOYSA-N N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-N-propylbenzamide Chemical compound FC1=CC2=C(C(=NO2)C2CCN(CC2)CCCN(C(C2=CC=CC=C2)=O)CCC)C=C1 SMPWWFQZWFWYBE-UHFFFAOYSA-N 0.000 description 2
- TYKZFVYOFIERGU-UHFFFAOYSA-N N-propyl-N-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]benzamide Chemical compound C(CC)N(C(C1=CC=CC=C1)=O)CCCN1CCN(CC1)C1=NC=CC=C1 TYKZFVYOFIERGU-UHFFFAOYSA-N 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical class ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012453 solvate Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- AVFRXIMUXZPJJV-UHFFFAOYSA-N 1-(3-chloropropyl)-4-(2,3-dichlorophenyl)piperazine Chemical compound C1CN(CCCCl)CCN1C1=CC=CC(Cl)=C1Cl AVFRXIMUXZPJJV-UHFFFAOYSA-N 0.000 description 1
- OIZBMQFOSPOOIS-UHFFFAOYSA-N 1-(3-chloropropyl)-4-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCN(CCCCl)CC1 OIZBMQFOSPOOIS-UHFFFAOYSA-N 0.000 description 1
- NYTSNMOIRVOWOC-UHFFFAOYSA-N 1-(3-chloropropyl)-4-pyridin-2-ylpiperazine Chemical compound C1CN(CCCCl)CCN1C1=CC=CC=N1 NYTSNMOIRVOWOC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 description 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FJEZAOCOLXYADV-UHFFFAOYSA-N 3-chloro-1-(4-pyridin-2-ylpiperazin-1-yl)propan-1-one Chemical compound C1CN(C(=O)CCCl)CCN1C1=CC=CC=N1 FJEZAOCOLXYADV-UHFFFAOYSA-N 0.000 description 1
- YMHBKEVWWRFOIL-UHFFFAOYSA-N 3-chloro-1-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-one Chemical compound COC1=CC=CC=C1N1CCN(C(=O)CCCl)CC1 YMHBKEVWWRFOIL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- MNIDYFHQOWZLQQ-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)N1CCN(CC1)CCCNC(C1=CC=CC=C1)=O Chemical compound ClC1=C(C=CC=C1Cl)N1CCN(CC1)CCCNC(C1=CC=CC=C1)=O MNIDYFHQOWZLQQ-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- QNARIGRIJHAUAQ-UHFFFAOYSA-N N-[3-[4-(2,3-dichlorophenyl)piperazin-1-yl]propyl]-N-(oxetan-3-yl)benzamide Chemical compound ClC1=C(C=CC=C1Cl)N1CCN(CC1)CCCN(C(C1=CC=CC=C1)=O)C1COC1 QNARIGRIJHAUAQ-UHFFFAOYSA-N 0.000 description 1
- RQUQHVGVVJGONQ-UHFFFAOYSA-N N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-N-(oxetan-3-yl)benzamide Chemical compound COC1=C(C=CC=C1)N1CCN(CC1)CCCN(C(C1=CC=CC=C1)=O)C1COC1 RQUQHVGVVJGONQ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000002243 precursor Chemical class 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and relates to an aryl piperazine/piperidine compound and application thereof, in particular to the aryl piperazine/piperidine compound which can be used as dopamine D 2 Receptors and 5-HT 2A The dual receptor antagonists are useful for the preparation of medicaments for the treatment or amelioration of neurological disorders, particularly schizophrenia. The general structural formula of the aryl piperazine/piperidine compound is as follows:wherein R is 1 、R 2 、R 3 、R 4 、X 1 、X 2 See the description for the definitions of A, m and n. The compound can be used as dopamine D 2 Receptor and 5-HT 2A The dual receptor antagonists are useful for the preparation of medicaments for the treatment or amelioration of neurological disorders, particularly schizophrenia.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an aryl piperazine/piperidine compound and application thereof. More specifically, the aryl piperazine/piperidine compound can be used as dopamine D 2 Receptors and 5-HT 2A Use of dual receptor antagonists for the preparation of a medicament for the treatment or amelioration of neurological disorders, particularly schizophreniaThe application of the medicine is provided.
Background
With the increasing work and life pressure of people, mental problems have serious adverse effects on the whole society. Schizophrenia (schizophrenia) is the most common serious continuous and chronic mental disease, and clinical manifestations comprise positive symptoms and negative symptoms, wherein the former symptoms comprise hallucinations, delusions, chorea and the like; the latter mainly refers to defective recognition function, learning and memory disorder, working and memory disorder, etc. Early first generation anti-schizophrenia drugs, also known as classical antipsychotics, were primarily responsible for positive Symptoms, have poor efficacy for negative Symptoms, and have a high incidence of Extrapyramidal Symptoms (EPS). Clozapine was invented at the end of the 60's 20 th century, which has a very good therapeutic effect on the positive symptoms of schizophrenia, also has a certain improvement on cognitive dysfunction, and does not cause obvious EPS and dyskinesia, and is called an atypical antipsychotic. In clinical use, clozapine, an anti-schizophrenia drug, has good efficacy, but some patients cause severe granulocytopenia and some even fatal agranulocytosis. Therefore, there is a great need to develop a second generation of atypical antipsychotics that are novel in structure and have low toxic side effects.
Researches show that the pathogenesis of schizophrenia is relatively complex, and genetic factors, character factors, psychological factors, environmental factors, body physiological factors and the like are involved, and the genetic factors play an important role in the pathogenesis of schizophrenia, but the pathogenesis of schizophrenia is not clear. The accepted argument for neurotransmitter imbalance in the brain states that the patient targets positive symptoms in the subcortical structures, D in these areas of the brain 2 Hyperactivity of the receptor, producing positive symptoms, all with D 2 Both classical and non-classical antipsychotics with receptor antagonism have good therapeutic effects on positive symptoms; the negative symptoms and cognitive impairment in the patient are due to D on the prefrontal lobe of the cerebral cortex 1 Low receptor function, D 1 Receptor agonists improve learning and memory disorders; d 3 The research on the receptor clone shows that the D can be blocked 2 Receptor antipsychotics also block D 3 A receptor; dopamine neuron upper surfaceUp to 5-HT 2A A receptor; thus, development of a composition having dopamine receptor and 5-HT 2A The second generation of atypical antipsychotics with dual receptor inhibition are key to the development of novel anti-schizophrenia drugs with high efficacy and low toxic side effects.
Based on the current situation and the defects of the prior art, the inventor of the application intends to provide an aryl piperazine/piperidine compound and application thereof, in particular to application of the aryl piperazine/piperidine compound in preparing medicines for treating or improving nervous system diseases, particularly schizophrenia.
Disclosure of Invention
The invention aims to provide an aryl piperazine/piperidine compound aiming at the defects in the prior art.
The invention also aims to provide a preparation method of the aryl piperazine/piperidine compound.
The invention also aims to provide the application of the compound in preparing medicaments for treating neurological and psychiatric diseases related to the brain, in particular schizophrenia.
The invention provides an aryl piperazine/piperidine compound shown in the following general formulas (I) and (II) and pharmacologically acceptable inorganic or organic salt and crystal hydrate thereof:
wherein:
X 1 、X 2 is carbon or nitrogen;
n is optionally selected from 0,1,2,3 or 4, preferably 3;
a is independently selected from carbonyl or-SO 2 -a group.
Substituent R 1 Optionally selected from H and C 1 -C 6 Substituted or unsubstituted alkyl, C 3 -C 7 Substituted or unsubstituted cycloalkyl, hetAr1, - (CH) 2 ) m -C 3 -C 7 Substituted or unsubstituted cycloalkyl, - (CH) 2 ) m -HetAr1, m =1 or 2, preferably selected from n-propyl, - (CH), isopropyl, - (CH) 2 ) -cyclopropyl, oxa-ringBut-3-yl;
substituent R 2 Absent or in at least one of the 2,3, 4, 5, 6 positions, being unsubstituted, mono-, di-or poly-substituted, the substituent R 2 One, two or more selected from the following groups: hydrogen, halogen, nitro, hydroxy, carboxy, trifluoromethyl, cyano, amino, phenyl, C 1 -C 6 Substituted or unsubstituted alkyl, C 1 -C 6 Substituted or unsubstituted alkoxy; when R is 2 When di-or tri-substituted, the substituents may be the same or different; preferably, the substituent R 2 Absent or at the 4-position, F, cyano, trifluoromethyl;
substituent R 3 Absent or in at least one of the 2,3, 4, 5, 6 positions, being unsubstituted, monosubstituted, disubstituted or polysubstituted, the substituents R 3 One, two or more selected from the following groups: hydrogen, halogen, nitro, hydroxy, carboxy, trifluoromethyl, cyano, amino, phenyl, C 1 -C 6 Substituted or unsubstituted alkyl, C 1 -C 6 A substituted or unsubstituted alkoxy group; when R is 3 When di-or tri-substituted, the substituents may be the same or different; preferably, the substituent R 3 Absent or methoxy at the 2-position, or Cl at the 2-and 3-positions.
Substituent R 4 Absent or in at least one of the 4, 5, 6, 7 positions, being unsubstituted, mono-, di-or poly-substituted, the substituent R 4 One, two or more selected from the following groups: hydrogen, halogen, nitro, hydroxy, carboxy, trifluoromethyl, cyano, amino, phenyl, C 1 -C 6 Substituted or unsubstituted alkyl, C 1 -C 6 Substituted or unsubstituted alkoxy; when R is 4 When di-or tri-substituted, the substituents may be the same or different; preferably, the substituent R 4 Is F at position 6;
unless otherwise indicated, C in the present invention 1 -C 6 Alkyl (C) 1 -C 6 Unsubstituted alkyl) is C 1 -C 6 Straight chain orBranched alkyl refers to alkyl groups containing 1 to 6 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, or octyl. C 1 -C 6 Substituted alkyl is C 1 -C 6 The alkyl group may be selected from hydroxy, halogen, C 1 -C 3 1-2 identical or different substituents of the alkoxy radical.
Unless otherwise indicated, C is defined herein 1 -C 6 Alkoxy (C) 1 -C 6 Unsubstituted alkoxy) is C 1 -C 6 Straight-chain or branched alkoxy means alkoxy containing 1 to 6 carbon atoms, including but not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, heptyloxy or octyloxy. C 1 -C 6 Substituted alkoxy means C 1 -C 6 Alkoxy groups may be selected from hydroxy and C 1 -C 3 1-2 identical or different substituents of the alkoxy radical.
Unless otherwise indicated, C in the present invention 3 -C 7 Cycloalkyl (C) 3 -C 7 Unsubstituted cycloalkyl) refers to cycloalkyl groups containing 3 to 7 carbon atoms, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropylcyclopentyl, cyclopropylcyclohexyl. C 3 -C 7 Substituted cycloalkyl is C 3 -C 7 Cycloalkyl groups may be selected from halogen, carbonyl, hydroxy and C 1 -C 3 1-2 identical or different substituents of the alkoxy radical.
Unless otherwise indicated, C in the present invention 1 -C 3 Alkoxy means C 1 -C 3 Straight or branched chain alkoxy refers to alkoxy containing 1 to 3 carbon atoms, including but not limited to methoxy, ethoxy, n-propoxy and isopropoxy.
HetAr1 as described herein represents a saturated unsubstituted 4, 5, 6, 7, 8, 9 or 10 membered heterocyclic ring having 1,2 or 3N and/or O and/or S atoms, unless otherwise specified.
Unless otherwise indicated, the term halogen is a halogen substituent, including but not limited to fluorine, chlorine, bromine, or iodine.
In the present invention, the terms "polysubstituted" and "plural" mean three or more, and the same meanings are given below.
In a preferred embodiment, the arylpiperazine/piperidine derivative of the present invention is a specific compound as follows:
n- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N-propylbenzamide,
n- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N-isopropylbenzamide,
N-cyclopropylmethyl-N [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] benzamide,
n- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzamide,
n- [3- [4- (2, 3-dichlorophenyl) piperazin-1-yl ] propyl ] -N-propylbenzamide,
n- [3- [4- (2, 3-dichlorophenyl) piperazin-1-yl ] propyl ] -N-isopropylbenzamide,
N-cyclopropylmethyl-N [3- [4- (2, 3-dichlorophenyl) piperazin-1-yl ] propyl ] benzamide,
n- [3- [4- (2, 3-dichlorophenyl) piperazin-1-yl ] propyl ] -N- (oxetan-3-yl) benzamide,
n- [3- [4- (pyridin-2-yl) piperazin-1-yl ] propyl ] -N-propylbenzamide,
n- [3- [4- (pyridin-2-yl) piperazin-1-yl ] propyl ] -N-isopropylbenzamide,
N-cyclopropylmethyl-N [3- [4- (pyridin-2-yl) piperazin-1-yl ] propyl ] benzamide,
n- [3- [4- (pyridin-2-yl) piperazin-1-yl ] propyl ] -N- (oxetan-3-yl) benzamide,
n- [3- [4- (2-methoxyphenyl) piperazin-1-yl ] propyl ] -N-propylbenzamide,
n- [3- [4- (2-methoxyphenyl) piperazin-1-yl ] propyl ] -N-isopropylbenzamide,
N-cyclopropylmethyl-N [3- [4- (2-methoxyphenyl) piperazin-1-yl ] propyl ] benzamide,
n- [3- [4- (2-methoxyphenyl) piperazin-1-yl ] propyl ] -N- (oxetan-3-yl) benzamide,
n- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide,
n- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) -1-benzylsulfonamide,
4-fluoro-N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide,
4-chloro-N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide,
4-trifluoromethyl-N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide,
4-cyano-N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide.
In the invention, pharmaceutically acceptable salts, solvates, precursor compounds or polymorphs of the aryl piperazine/piperidine derivatives are also included.
A pharmaceutically acceptable salt, solvate, prodrug or polymorph, wherein the pharmaceutically acceptable salt is an inorganic salt, an organic salt or an amino acid salt;
wherein the inorganic salt is: sodium salts, hydrochlorides, trifluoroacetates, sulfates, phosphates, diphosphates, hydrobromides or nitrates;
wherein the organic salt is: maleate, acetate, fumarate, tartrate, succinate, lactate, p-toluenesulfonate, salicylate, or oxalate;
wherein the amino acid salt is: arginine salt, ornithine salt, lysine salt, leucine salt, isoleucine salt, glycine salt, cystine salt, cysteine salt, caseinate, alanine salt, phenylalanine salt, histidine salt, serine salt, threonine salt, methionine salt, tryptophan salt, glutamate, aspartate salt, valine salt, methionine salt, proline salt, or hydroxyproline salt.
In order to achieve the second purpose, the invention adopts the technical scheme that:
the preparation method of the aryl piperazine/piperidine derivative can be synthesized through the following steps:
preparation of intermediates 2a,2b
And reacting the compounds 1a and 1b with 3-chloropropionyl chloride in a dichloromethane solvent under the basic condition of triethylamine to generate the compounds 2a and 2b.
Preparation of intermediate 3a,3b
And reacting the compounds 2a and 2b with borane-dimethyl sulfide complex in a tetrahydrofuran solvent under the protection of nitrogen to generate the compounds 3a and 3b.
Preparation of intermediate 4a,4b
And heating the compound 3a,3b and the corresponding amine derivative in an acetonitrile solvent under the alkaline condition of potassium carbonate to react to generate the compound 4a,4b.
Preparation of Compounds I, II
Reacting the compound 4a,4b with a corresponding benzoic acid derivative, HATU in a dichloromethane solvent under the basic condition of N, N-diisopropylethylamine to generate a compound I and a compound II; or the compound 4a,4b reacts with the corresponding benzenesulfonyl chloride derivative in a dichloromethane solvent under the basic condition of N, N-diisopropylethylamine to generate the compounds I and II.
Among them, the process for preparing a pharmaceutically acceptable salt of the arylpiperazine/piperidine derivative may be carried out according to a conventional method in the art, and the compound of the present invention is usually isolated as it is, or obtained by reacting it with an inorganic salt, an organic salt or an amino acid salt under a conventional condition in the form of a pharmaceutically acceptable salt.
The biological activity of the compounds encompassed by the present invention at dopamine and serotonin receptors is illustrated by the results of pharmacological experiments as follows:
1. experimental methods
D 2 Receptor antagonistic Activity with 5-HT 1A Experimental methods for receptor agonistic activity: ultra Lance cAMP Assay
5-HT 2A Receptor antagonistic activity assay methods: FLIPR Assay.
2. The results of the experiment are shown in table 1:
table 1 pharmacological test results of the compounds
The results show that most of the novel compounds show a certain degree of dopamine receptor and 5-HT receptor multi-target activity, wherein the 6-fluorobenzoisoxazole piperidine compound shows stronger D 2 And 5-HT 2A Dual antagonistic activity.
The compound can be used as a lead compound to further develop multi-target compounds with high activity aiming at dopamine receptors and 5-HT receptors, and is used for preparing potential medicaments for treating neurological and psychiatric diseases related to the brain, in particular to medicaments for resisting schizophrenia.
Detailed Description
The invention will now be further illustrated, but not limited, by the following examples.
1 H-NMR was measured using a Varian Mercury Plus 400Hz model instrument; for MSAgilent 6120Quadrupole LC/MS determination, redistilling all solvents before using, and drying the used anhydrous solvent according to a standard method to obtain; all reactions were followed by TLC except as indicated, and work-up was by washing with saturated aqueous sodium chloride and drying over anhydrous sodium sulfate; purifying the product by silica gel (200-300 meshes) column chromatography except for the specification; wherein the silica gel (200-300 meshes) is produced by Qingdao ocean chemical plants, and the TLC plate is a Qingdao ocean 0.2mm GF245 high-efficiency thin-layer chromatography silica gel plate.
Example 1: preparation of N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N-propylbenzamide (FW-WQ I-01)
Step 1: preparation of 3-chloro-1- [4- (6-fluoro-1, 2-benzisoxazolyl) piperidin-1-yl ] -1-propanone (intermediate 2A)
In a dry 100ml single-neck flask, 3.56g (16 mmol) of 6-fluoro-3- (4-piperidinyl) -1, 2-benzisoxazole, 50ml of anhydrous dichloromethane and 2.70ml (19 mmol) of triethylamine were added successively under ice-water bath conditions, and 1.80ml (19 mmol) of 3-chloropropionyl chloride was slowly added dropwise, after completion, stirring was carried out at room temperature for 20min. After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to obtain 3.33g of white solid 2A. (yield: 67.1%)
Step 2: preparation of 3- [1- (3-chloropropyl) piperidin-4-yl ] -6-fluoro-1, 2 benzisoxazole (intermediate 3A)
Under the protection of nitrogen and ice-water bath, 2.85g (9.2 mmol) of compound 2A and 30ml of anhydrous tetrahydrofuran are added into a 250ml three-neck flask in sequence, 18ml (18 mmol) of 1.0mol/L borane-dimethyl sulfide complex is slowly injected, and after the completion, the mixture is moved to an 80 ℃ oil bath and heated and refluxed for 1h. After the reaction is finished, the system is cooled to room temperature, 90ml of methanol is slowly added to quench the reaction, and then the reaction is heated and refluxed for 2 hours in an oil bath at the temperature of 60 ℃. The reaction solution was transferred to a 250ml single-neck flask, the solvent was distilled off under reduced pressure, 50ml of methylene chloride was added, 20ml of water was extracted 3 times, a saturated aqueous sodium chloride solution was washed 3 times, dried over anhydrous sodium sulfate, and the solvent was spin-dried. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5). (yield: 64.2%)
And step 3: preparation of 3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] -N-propyl-1-propylamine (intermediate 4A)
In a 50ml single-neck flask were placed 0.50g (1.7 mmol) of compound 3A,0.26g (2.0 mmol) of potassium carbonate, 0.08mg (0.0005 mmol) of potassium iodide, 20ml of acetonitrile and 0.17ml (2.0 mmol) of n-propylamine in that order, and heated in a 75 ℃ oil bath under reflux for 6 hours. After the reaction, the system is cooled to room temperature, the solvent is removed by distillation under reduced pressure, 30ml of dichloromethane and 15ml of water are added for extraction for three times, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol = 40). (yield: 20.4%)
And 4, step 4: preparation of N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N-propylbenzamide (FW-WQ I-01)
In a 100ml single-neck flask were successively charged 0.17g (1.4 mmol) of benzoic acid, 0.52g (1.4 mmol) of HBTU,0.19g (1.4 mmol) of HOBT,30ml of methylene chloride and 0.29ml (2.0 mmol) of N, N-diisopropylethylamine, and after stirring at room temperature for 30min, 0.30g (0.94 mmol) of Compound 4A was added and stirred at room temperature overnight. After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, and the solvent is dried by anhydrous sodium sulfate and spin-dried. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol =40 = 1) to obtain 0.24g of a yellow oily compound FW-WQ i-01. (yield: 60.3%)
Examples 2 to 4: compound FW-WQI-02-FW-WQI-04
Example 1 was repeated, with the difference that: in step 3, different raw materials are used to prepare the compound FW-WQI-02-FW-WQI-04. The details are shown in the following table:
example 5: preparation of N- [3- [4- (2, 3-dichlorophenyl) piperazin-1-yl ] propyl ] -N-propylbenzamide (FW-WQI-05)
Step 1: preparation of 3-chloro-1- [4- (2, 3-dichlorophenyl) piperazin-1-yl ] -1-propanone (intermediate 2B)
In a dry 100ml single-neck flask, 3.72g (16 mmol) of 1- (2, 3-dichlorophenyl) piperazine, 50ml of anhydrous dichloromethane and 2.70ml (19 mmol) of triethylamine were added successively under ice-water bath condition, and 1.80ml (19 mmol) of 3-chloropropionyl chloride was slowly added dropwise, after completion, stirring was carried out at room temperature for 20min. After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to obtain 3.47g of white solid 2B. (yield: 67.1%)
Step 2: preparation of 1- (3-chloropropyl) -4- (2, 3-dichlorophenyl) piperazine (intermediate 3B)
Under the protection of nitrogen and ice-water bath, 2.95g (9.2 mmol) of compound 2B and 30ml of anhydrous tetrahydrofuran are added into a 250ml three-neck flask in sequence, 18ml (18 mmol) of 1.0mol/L borane-dimethyl sulfide complex is slowly injected, and after the completion, the mixture is moved to an 80 ℃ oil bath and heated and refluxed for 1h. After the reaction is finished, cooling the system to room temperature, slowly adding 90ml of methanol to quench the reaction, and then heating and refluxing for 2 hours in an oil bath at 60 ℃. The reaction solution was transferred to a 250ml single-neck flask, the solvent was distilled off under reduced pressure, 50ml of methylene chloride was added, 20ml of water was extracted 3 times, a saturated aqueous sodium chloride solution was washed 3 times, dried over anhydrous sodium sulfate, and the solvent was spin-dried. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to give 2.12g of compound 3B as a colorless oily substance. (yield: 64.2%)
And step 3: preparation of 3- [4- (2, 3-dichlorophenyl) piperazin-1-yl ] -N-propyl-1-propylamine (intermediate 4B)
In a 50ml single-neck flask were placed 0.50g (1.6 mmol) of compound 3B,0.26g (2.0 mmol) of potassium carbonate, 0.08mg (0.0005 mmol) of potassium iodide, 20ml of acetonitrile and 0.16ml (2.0 mmol) of n-propylamine in that order, and heated in a 75 ℃ oil bath under reflux for 6 hours. After the reaction, the system is cooled to room temperature, the solvent is removed by distillation under reduced pressure, 30ml of dichloromethane and 15ml of water are added for extraction for three times, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol = 40). (yield: 88.5%)
And 4, step 4: preparation of N- [3- [4- (2, 3-dichlorophenyl) piperazin-1-yl ] propyl ] -N-propylbenzamide (FW-WQI-05)
In a 100ml single-neck flask were successively charged 0.28g (2.3 mmol) of benzoic acid, 0.86g (2.3 mmol) of HBTU,0.31g (2.3 mmol) of HOBT,30ml of methylene chloride and 0.5ml (3.0 mmol) of N, N-diisopropylethylamine, and after stirring at room temperature for 30min, 0.50g (1.5 mmol) of Compound 4B was added and stirred at room temperature overnight. After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol =40 = 1) to obtain 0.46g of a yellow oily compound FW-wqi-05. (yield: 92.0%)
Examples 6 to 8: compound FW-WQI-06-FW-WQI-08
Example 5 was repeated, with the difference that: in step 3, different raw materials are used to prepare a compound FW-WQI-06-FW-WQI-08. The following table specifically shows:
example 9: preparation of N- [3- [4- (pyridin-2-yl) piperazin-1-yl ] propyl ] -N-propylbenzamide (FW-WQI-09)
Step 1: preparation of 3-chloro-1- [4- (pyridin-2-yl) piperazin-1-yl ] -1-propanone (intermediate 2C)
32.8ml (18 mmol) of 1- (2-pyridyl) piperazine, 50ml of anhydrous dichloromethane and 3.13ml (19 mmol) of triethylamine are added in sequence to a dry 100ml single-neck flask under the condition of ice-water bath, 2.1ml (22 mmol) of 3-chloropropionyl chloride is slowly dropped, and after completion, the mixture is stirred at room temperature for 20min. After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, and the solvent is dried by anhydrous sodium sulfate and spin-dried. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to give 4.15g of compound 2C as a colorless oil. (yield: 89.1%)
Step 2: preparation of 1- (3-chloropropyl) -4- (pyridin-2-yl) piperazine (intermediate 3C)
4.15g (10 mmol) of compound 2C and 30ml of anhydrous tetrahydrofuran are added in turn to a 250ml three-neck flask under the protection of nitrogen and ice-water bath, 20ml (20 mmol) of 1.0mol/L borane-dimethyl sulfide complex is injected slowly, and after completion, the mixture is moved to an oil bath at 80 ℃ and heated and refluxed for 1h. After the reaction is finished, cooling the system to room temperature, slowly adding 90ml of methanol to quench the reaction, and then heating and refluxing for 2 hours in an oil bath at 60 ℃. The reaction solution was transferred to a 250ml single-neck flask, the solvent was distilled off under reduced pressure, 50ml of methylene chloride was added, 20ml of water was extracted 3 times, a saturated aqueous sodium chloride solution was washed 3 times, dried over anhydrous sodium sulfate, and the solvent was spin-dried. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to obtain 2.98g of compound 3C as a colorless oil. (yield: 76.4%)
And step 3: preparation of 3- [4- (pyridin-2-yl) piperazin-1-yl ] -N-propyl-1-propylamine (intermediate 4C)
In a 50ml single-neck flask were placed 0.4g (1.7 mmol) of compound 3C,0.26g (2.0 mmol) of potassium carbonate, 0.08mg (0.0005 mmol) of potassium iodide, 20ml of acetonitrile and 0.16ml (2.0 mmol) of n-propylamine in that order, and heated in a 75 ℃ oil bath under reflux for 6 hours. After the reaction, the system is cooled to room temperature, the solvent is removed by distillation under reduced pressure, 30ml of dichloromethane and 15ml of water are added for extraction for three times, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol =40 = 1) to obtain 0.41g of compound 4C as a yellow oil. (yield: 89.1%)
And 4, step 4: preparation of N- [3- [4- (pyridin-2-yl) piperazin-1-yl ] propyl ] -N-propylbenzamide (FW-WQ I-09)
In a 100ml one-neck flask were successively charged 0.28g (2.3 mmol) of benzoic acid, 0.86g (2.3 mmol) of HBTU,0.31g (2.3 mmol) of HOBT,30ml of methylene chloride and 0.5ml (3.0 mmol) of N, N-diisopropylethylamine, and after stirring at room temperature for 30min, 0.53g (2.0 mmol) of Compound 4C was added, and the mixture was stirred at room temperature overnight. . After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol =40 = 1) to obtain 0.48g of a yellow oily compound FW-wqi-09. (yield: 65.5%)
Examples 10 to 12: compound FW-WQI-10-FW-WQI-12
Example 9 was repeated, with the difference that: in step 3, different starting materials are used to produce the compound FW-WQI-10-FW-WQI-12. The following table specifically shows:
example 13: preparation of N- [3- [4- (2-methoxyphenyl) piperazin-1-yl ] propyl ] -N-propylbenzamide (FW-WQI-13)
Step 1: preparation of 3-chloro-1- [4- (2-methoxyphenyl) piperazin-1-yl ] -1-propanone (intermediate 2D)
In a dry 100ml single-neck flask under the condition of ice-water bath, 4.00g (21 mmol) of 1- (2-methoxyphenyl) piperazine, 50ml of anhydrous dichloromethane and 3.55ml (19 mmol) of triethylamine are added in sequence, 2.4ml (25 mmol) of 3-chloropropionyl chloride is slowly dropped, and after completion, the mixture is stirred at room temperature for 20min. After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to obtain 3.02g of compound 2D as a colorless oily substance. (yield: 50.9%)
Step 2: preparation of 1- (3-chloropropyl) -4- (2-methoxyphenyl) piperazine (intermediate 3D)
Under the protection of nitrogen and ice-water bath, 3.02g (11 mmol) of compound 2D and 30ml of anhydrous tetrahydrofuran are sequentially added into a 250ml three-neck flask, 20ml (20 mmol) of 1.0mol/L borane-dimethyl sulfide complex is slowly injected, and after the completion, the mixture is moved to an 80 ℃ oil bath to be heated and refluxed for 1h. After the reaction is finished, cooling the system to room temperature, slowly adding 90ml of methanol to quench the reaction, and then heating and refluxing for 2 hours in an oil bath at 60 ℃. The reaction solution was transferred to a 250ml single-neck flask, the solvent was distilled off under reduced pressure, 50ml of methylene chloride and 20ml of water were added to extract 3 times, the mixture was washed with saturated aqueous sodium chloride solution 3 times, dried over anhydrous sodium sulfate, and the solvent was spin-dried. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to give 1.50g of compound 3D as a colorless oil. (yield: 50.8%)
And step 3: preparation of 3- [4- (2-methoxyphenyl) piperazin-1-yl ] -N-propyl-1-propylamine (intermediate 4D)
In a 50ml single-neck flask were charged 0.4g (1.5 mmol) of compound 3,0.26g (2.0 mmol) of potassium carbonate, 0.08mg (0.0005 mmol) of potassium iodide, 20ml of acetonitrile and 0.15ml (1.8 mmol) of n-propylamine in this order, and heated in a 75 ℃ oil bath under reflux for 6 hours. After the reaction, the system is cooled to room temperature, the solvent is removed by distillation under reduced pressure, 30ml of dichloromethane and 15ml of water are added for extraction for three times, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol = 40). (yield: 56.8%)
And 4, step 4: preparation of N- [3- [4- (2-methoxyphenyl) piperazin-1-yl ] propyl ] -N-propylbenzamide (FW-WQ I-13)
In a 100ml single-neck flask were successively charged 0.28g (2.3 mmol) of benzoic acid, 0.86g (2.3 mmol) of HBTU,0.31g (2.3 mmol) of HOBT,30ml of methylene chloride and 0.5ml (3.0 mmol) of N, N-diisopropylethylamine, and after stirring at room temperature for 30min, 0.36g (1.2 mmol) of Compound 4D was added and stirred at room temperature overnight. After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, and the solvent is dried by anhydrous sodium sulfate and spin-dried. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol =40 = 1) to obtain 0.35g of a yellow oily compound FW-WQ i-13. (yield: 73.8%)
Examples 14 to 16: compound FW-WQI-14-FW-WQI-16
Example 13 was repeated, with the difference that: in step 3, different starting materials are used to produce the compound FW-WQI-14-FW-WQI-16. The method comprises the following specific steps:
example 17: preparation of N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide (FW-WQ I-17)
Step 1: preparation of 3-chloro-1- [4- (6-fluoro-1, 2 benzisoxazolyl) piperidin-1-yl ] -1-propanone (intermediate 2A)
In a dry 100ml single-neck flask, 3.56g (16 mmol) of 6-fluoro-3- (4-piperidinyl) -1, 2-benzisoxazole, 50ml of anhydrous dichloromethane and 2.70ml (19 mmol) of triethylamine were added successively under ice-water bath conditions, and 1.80ml (19 mmol) of 3-chloropropionyl chloride was slowly added dropwise, after completion, stirring was carried out at room temperature for 20min. After the reaction, 50ml of water and 20ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to obtain 3.33g of a white solid 2A. (yield: 67.1%)
Step 2: preparation of 3- [1- (3-chloropropyl) piperidin-4-yl ] -6-fluoro-1, 2 benzisoxazole (intermediate 3A)
Under the protection of nitrogen and ice-water bath, 2.85g (9.2 mmol) of compound 2A and 30ml of anhydrous tetrahydrofuran are added into a 250ml three-neck flask in sequence, 18ml (18 mmol) of 1.0mol/L borane-dimethyl sulfide complex is slowly injected, and after the completion, the mixture is moved to an 80 ℃ oil bath and heated and refluxed for 1h. After the reaction is finished, cooling the system to room temperature, slowly adding 90ml of methanol to quench the reaction, and then heating and refluxing for 2 hours in an oil bath at 60 ℃. The reaction solution was transferred to a 250ml single-neck flask, the solvent was distilled off under reduced pressure, 50ml of methylene chloride was added, 20ml of water was extracted 3 times, a saturated aqueous sodium chloride solution was washed 3 times, dried over anhydrous sodium sulfate, and the solvent was spin-dried. The crude compound was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5) to give 1.75g of compound 3A as a colorless oil. (yield: 64.2%)
And step 3: preparation of N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] oxetan-3-amine (intermediate 4E)
In a 50ml single-neck flask were placed 0.50g (1.7 mmol) of compound 3A,0.26g (2.0 mmol) of potassium carbonate, 0.08mg (0.0005 mmol) of potassium iodide, 20ml of acetonitrile and 0.14ml (2.0 mmol) of 3-oxetane in that order, and heated under reflux for 6h in a 75 ℃ oil bath. After the reaction, the system is cooled to room temperature, the solvent is removed by distillation under reduced pressure, 30ml of dichloromethane and 15ml of water are added for extraction for three times, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol = 40). (yield: 64.3%)
And 4, step 4: preparation of N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide (FW-WQ I-17)
0.17g (0.51 mmol) of Compound 4E,20ml of anhydrous dichloromethane and 0.17ml (1.02 mmol) of N, N-diisopropylethylamine were sequentially added to a 50ml single-neck flask under an ice-water bath condition, and 0.08ml (0.61 mmol) of benzenesulfonyl chloride was slowly added dropwise thereto, followed by stirring at room temperature for 6 hours. After the reaction, 30ml of water and 10ml of dichloromethane are added for extraction for 3 times, organic phases are combined, saturated sodium chloride aqueous solution is washed for 3 times, anhydrous sodium sulfate is dried, and the solvent is dried in a spinning mode. The crude compound was subjected to silica gel column chromatography (dichloromethane: methanol =40 = 1) to obtain 0.14g of a yellow oily compound FW-WQ i-17. (yield: 58.3%)
Examples 18 to 22: compound FW-WQI-18-FW-WQI-22
Example 17 was repeated, with the difference that: different raw materials are used in the step 4, thereby obtaining FW-WQI-18-FW-WQI-22. The following table specifically shows:
the chemical structure of the synthesized target product is shown in table 2; the nuclear magnetic hydrogen spectrum and mass spectrum system characterize the chemical structure of the target product.
TABLE 2 chemical structure of target product, nuclear magnetic hydrogen spectrum, mass spectrum data
Example 23: example of pharmacological practice
Ultra Lance Camp Assay&FLIPR Assay
1. Experimental Material
An experimental instrument: multi-label detection analyzer Envision Multilabel Reader (from PerkinEImer), ultrasonic nanoliter liquid handling system Echo 550 (from LABCYTE), automatic micropore pipettor PRC3840Precision (from BioTek), centrifuge 5810R (from eppendorf), nucleoCounter (from ChemoMetec), carbon dioxide incubator 3111CO 2 Incubator (ex Thermo), inverted Microscope CKX41Microscope (ex OLYMPUS). Cell: stable expression of 5-HT by genetic recombination 1A Recipient HEK-293 cells. Stable expression of D by Gene recombination 2 Receptor, 5-HT 2A CHO-K1 cells of the recipient. Positive drugs: risperidone (D) 2 R、5-HT 2A R)、8-OH-DPAT(5-HT 1A R)。
2. Experimental methods
Ultra Lance cAMP Assay:
1. 100nl of each concentration of compound was transferred to each individual well of a 384-well plate by the ultrasonic nanoliter liquid handling system Echo 550.
2. Cells were harvested using stimulation buffer: 1) Remove the cell culture medium and rinse the cells with 5ml of PBS solution; 2) Extracting PBS solution, adding 3ml Trypsin, and incubating in 37 deg.C incubator for 2-5min; 3) Adding 10ml of culture medium to suspend cells, and taking 50 mu l of cell suspension for cell counting; 4) The cell suspension is brought to the appropriate concentration.
3. Reaction: 1) Add 10. Mu.l of cell solution to each single well of 384-well plate; 2) Centrifuging at 600rpm for 3min, and incubating at room temperature for 60min; 3) Each single well was spiked with 5. Mu.l of 4 × Eu-cAMP tracer and 5. Mu.l of 4 × ULight TM -anti-cAMP solution; 4) Centrifuging at 600rpm for 3min, and incubating at room temperature for 60min.
4. Reading results with a multi-marker detection analyzer
FLIPR Assay:
1. And (3) cell culture: 1) Remove the cell culture medium and rinse the cells with 5ml of PBS solution; 2) The PBS solution was extracted and 2ml Versene was added; 3) Adding 10ml of culture medium to suspend cells, and taking 50 mu l of cell suspension for cell counting; 4) Preparing the cell suspension to a suitable concentration; 5) Add 50. Mu.l of cell suspension to each individual well of 384-well plate; 6) Incubate 384-well plates at 37 ℃,5% in a CO2 incubator for 16-24h.
FLIPR Assay: 1) The 384 well plates were removed from the incubator, the supernatant removed, and 30 μ l 1 × dye added; 2) Incubating the 384-well plate at 37 ℃ for 1h in an incubator 5% CO2; 3) Adding 30 μ l of assay buffer into each single hole and shaking for 20-40min; 4) Placing 384-well plates on a FLIPR, adding 15 mu l of each concentration of compound solution into each single well, and detecting a calcium flow signal; after 15min, 22.5 μ l of EC80 agonist was added to each individual well and calcium flux signals were detected. The% agonistic/antagonistic activity is calculated as follows:
% agonistic/antagonistic activity = × 100%
Claims (7)
1. A compound represented by the general formula (II)
Wherein:
X 1 is carbon;
n is 3;
a is independently selected from carbonyl or-SO 2 -a group;
substituent R 1 Optionally selected from H and C 1 -C 6 Alkyl radical, C 3 -C 7 Cycloalkyl, hetAr1, - (CH) 2 ) m -C 3 -C 7 Cycloalkyl, - (CH) 2 ) m -HetAr1, m =1 or 2, said HetAr1 representing a saturated unsubstituted 4-membered heterocyclic ring having 1O atom;
substituent R 2 Absent or in position 4, substituent R 2 One selected from the following groups: hydrogen, halogen, trifluoromethyl, cyano;
substituent R 4 Absent or in position 6, substituent R 4 One selected from the following groups: hydrogen, halogen.
2. The compound of claim 1, wherein the compound is selected from the group consisting of:
n- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N-propylbenzamide
N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N-isopropylbenzamide
N-cyclopropylmethyl-N [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] benzamide
N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzamide
N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide
N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) -1-benzylsulfonamide
4-fluoro-N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide
4-chloro-N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide
4-trifluoromethyl-N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide
4-cyano-N- [3- [4- (6-fluoro-1, 2-benzisoxazol-3-yl) piperidin-1-yl ] propyl ] -N- (oxetan-3-yl) benzenesulfonamide.
3. A pharmaceutically acceptable salt of the compound of claim 1.
4. The pharmaceutically acceptable salt according to claim 3, wherein the pharmaceutically acceptable salt is an inorganic salt, an organic salt or an amino acid salt;
wherein the inorganic salt is: sodium salts, hydrochlorides, trifluoroacetates, sulfates, phosphates, diphosphates, hydrobromides or nitrates;
wherein the organic salt is: maleate, acetate, fumarate, tartrate, succinate, lactate, p-toluenesulfonate, salicylate, or oxalate;
wherein the amino acid salt is: arginine salt, ornithine salt, lysine salt, leucine salt, isoleucine salt, glycine salt, cystine salt, cysteine salt, caseinate, alanine salt, phenylalanine salt, histidine salt, serine salt, threonine salt, methionine salt, tryptophan salt, glutamate, aspartate salt, valine salt, methionine salt, proline salt, or hydroxyproline salt.
5. Use of a compound as claimed in claim 1 or a pharmaceutically acceptable salt as claimed in claim 3 in the manufacture of a medicament for treating or preventing dopamine D 2 Receptor and/or 5-HT 2A The use of a medicament for treating a receptor-related disease.
6. Use according to claim 5, wherein the disease is a neurological disease.
7. Use according to claim 6, characterized in that the disease is schizophrenia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810494866.0A CN110511215B (en) | 2018-05-22 | 2018-05-22 | Aryl piperazine/piperidine compound and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810494866.0A CN110511215B (en) | 2018-05-22 | 2018-05-22 | Aryl piperazine/piperidine compound and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110511215A CN110511215A (en) | 2019-11-29 |
CN110511215B true CN110511215B (en) | 2023-03-28 |
Family
ID=68622108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810494866.0A Active CN110511215B (en) | 2018-05-22 | 2018-05-22 | Aryl piperazine/piperidine compound and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110511215B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5135931A (en) * | 1990-06-11 | 1992-08-04 | Akzo N.V. | Pyridinylpiperazine derivatives |
JPH11171865A (en) * | 1997-12-04 | 1999-06-29 | Yoshitomi Pharmaceut Ind Ltd | Condensed heterocyclic compound |
US6660751B1 (en) * | 1999-03-23 | 2003-12-09 | Smithkline Beecham P.L.C. | Sulfonamide derivatives as 5-HT7 receptor antagonists |
CN105712952A (en) * | 2014-12-22 | 2016-06-29 | 上海翰森生物医药科技有限公司 | 2-Substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and preparation method and application thereof |
CN107793408A (en) * | 2016-09-05 | 2018-03-13 | 上海医药工业研究院 | Piperidines aminoderivative and its schizoid application for the treatment of |
-
2018
- 2018-05-22 CN CN201810494866.0A patent/CN110511215B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5135931A (en) * | 1990-06-11 | 1992-08-04 | Akzo N.V. | Pyridinylpiperazine derivatives |
JPH11171865A (en) * | 1997-12-04 | 1999-06-29 | Yoshitomi Pharmaceut Ind Ltd | Condensed heterocyclic compound |
US6660751B1 (en) * | 1999-03-23 | 2003-12-09 | Smithkline Beecham P.L.C. | Sulfonamide derivatives as 5-HT7 receptor antagonists |
CN105712952A (en) * | 2014-12-22 | 2016-06-29 | 上海翰森生物医药科技有限公司 | 2-Substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and preparation method and application thereof |
CN107793408A (en) * | 2016-09-05 | 2018-03-13 | 上海医药工业研究院 | Piperidines aminoderivative and its schizoid application for the treatment of |
Non-Patent Citations (3)
Title |
---|
Euna Yoo, et al..Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsul- fon amides as selective 5-HT2A receptor antagonists.《Bioorganic & Medicinal Chemistry》.2010,第8卷1665-1675. * |
RN2200296-33-7等;STN REGISTRY;《STN REGISTRY》;20180327;1-31 * |
Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsul- fon amides as selective 5-HT2A receptor antagonists;Euna Yoo, et al.;《Bioorganic & Medicinal Chemistry》;20100104;第8卷;1665-1675 * |
Also Published As
Publication number | Publication date |
---|---|
CN110511215A (en) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10611770B2 (en) | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | |
CN106188138B (en) | A kind of diaminopyrimidine compounds and the composition comprising the compound | |
CA2957046C (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
JP4436892B2 (en) | Pyridine [3,4-b] pyrazinone | |
CA3133753A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
US20040097574A1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
TW202003505A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
JP2016518316A (en) | MK2 inhibitors and their use | |
JP2010518026A (en) | Pyridopyrimidinone compounds useful for the treatment of diseases or conditions mediated by sodium channels | |
TW200538433A (en) | Immunosuppressant compounds and compositiions | |
CA2660560A1 (en) | Pyrazine compounds, their use and methods of preparation | |
CN106103432B (en) | Substituted thiazole or oxazole P2X7 receptor antagonist | |
PT2300472E (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
EA035544B1 (en) | Tetrahydroisoquinoline derivatives | |
CA2741400A1 (en) | Sulfonamide derivative metabotropic glutamate r4 ligands | |
WO2011133444A1 (en) | Substituted pyrimidines | |
KR20100052507A (en) | Novel heterocyclic compounds as mglu5 antagonists | |
JP2018521024A (en) | Muscarinic M1 receptor positive allosteric modulator | |
JP7190755B2 (en) | Oxazinoquinazoline and oxazinoquinoline compounds, and methods of preparation and uses thereof | |
EP3966208A2 (en) | Compounds and methods for treating cancer | |
JP2017100951A (en) | Oxazolidinone and oxazinanone derivative | |
US8258301B2 (en) | Urotensin II receptor antagonists | |
CN111566102B (en) | Substituted pyrrolopyridines as activin receptor-like kinase inhibitors | |
CA2937012A1 (en) | Fused pyrazole derivative | |
BR112016008654B1 (en) | BICYCLIC COMPOUNDS CONTAINING SULFUR, PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUNDS AND THERAPEUTIC USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |